NCT00848926 enrolled 102 relapsed or refractory HL patients and obtained an ORR of 75% (CR 34%) with a median duration of response (DoR) of 6.7 months.79 NCT00866047 showed an ORR of 86% (CR 57%) with a median DoR of 12.6 months in 58 patients with relapsed or refractory CD30+ ALCL.80 After approval, the FDA issued a boxed warning related to the risk of progressive multifocal leukoencephalopathy and added a contraindication warning for the concomitant use of BV and bleomycin due to pulmonary toxicity. The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.